Clinical trials · Texas
Cardiomyopathies clinical trials in Texas
We’re tracking 37 recruiting cardiomyopathies studies with a site in Texas — including Phase 1/Phase 2, Phase 2, Phase 2/Phase 3, Phase 3 and Phase 4 studies, each written for real people, not researchers.
Recruiting studies in Texas
- NCT07426419RecruitingPhase 1/Phase 2
Gene therapy for heart failure caused by BAG3 gene mutation
This trial tests a one-time gene therapy called AFTX-201 for people with dilated cardiomyopathy due to a BAG3 gene mutation. It aims to improve heart function and reduce heart failure symptoms.
Houston, TexasAges 18–55 - NCT07052903RecruitingPhase 3
RNA therapy for ATTR amyloidosis with heart involvement
This trial tests an experimental RNA therapy (nucresiran) for people with transthyretin amyloidosis that causes heart problems (cardiomyopathy). It aims to lower the abnormal protein buildup to help heart function.
Dallas, TexasAges 18–85 - NCT05180773RecruitingPhase 4
Bromocriptine for new postpartum heart weakness
This trial studies whether bromocriptine improves health outcomes in people recently diagnosed with peripartum cardiomyopathy (a weakened heart during late pregnancy or soon after delivery). You may be asked about timing after childbirth, heart strength tests, and whether you plan to keep breastfeeding.
Dallas, TexasAges 18 years+ - NCT07606274RecruitingPhase 1/Phase 2
Study of NVC-001 for heart muscle disease caused by LMNA gene change
This trial tests an experimental drug called NVC-001 for people with a specific genetic heart condition (LMNA-related dilated cardiomyopathy) that causes the heart to become weak and enlarged. The goal is to see if the drug can help improve heart function.
Houston, TexasAges 18 years+ - NCT04476901RecruitingPhase 2
Study of donor stem cell treatment for non-ischemic heart failure
This Phase 2 trial tests whether donor “MSC” cells can improve heart function in people with non-ischemic dilated cardiomyopathy and reduced pumping strength. You may be eligible if your condition is already treated with standard heart medicines and you can safely undergo a heart catheterization and follow-up testing.
Houston, TexasAges 18–80 - NCT07658222Recruiting
Understanding heart changes in advanced cirrhosis
This study is looking at how cirrhosis affects the heart (called cirrhotic cardiomyopathy). It aims to understand the connection between advanced liver disease and heart function, which may help improve care for people with cirrhosis.
Dallas, TexasAges 18 years+ - NCT07210723RecruitingPhase 2/Phase 3
Study of danicamtiv for genetic and familial dilated cardiomyopathy
This trial tests if danicamtiv can improve heart function in people with dilated cardiomyopathy caused by certain genetic changes. It may help those who have stable symptoms but still need more treatment options.
Houston, TexasAges 18 years+ - NCT07218887RecruitingPhase 1/Phase 2
A study of ALXN2350 for BAG3-related heart muscle disease
This trial tests a new medicine, ALXN2350, for adults whose dilated cardiomyopathy (a weakened, enlarged heart) is caused by a mutation in the BAG3 gene. The goal is to see if it can help the heart pump better.
Houston, TexasAges 18–70 - NCT06412666RecruitingPhase 2/Phase 3
Aficamten for teens with obstructive hypertrophic cardiomyopathy
This trial tests a new medicine called aficamten for teenagers with a heart condition that makes the heart muscle too thick and blocks blood flow. The medicine may help make the heart pump more easily and improve symptoms like shortness of breath or chest pain.
Austin, TexasAges 12–17 - NCT06563895RecruitingPhase 3
Testing acoramidis to prevent ATTR amyloidosis in gene carriers
This trial tests a daily pill called acoramidis to see if it can prevent ATTR amyloidosis in people who carry a gene mutation but have no symptoms yet. It aims to stop the disease before it starts.
Austin, TexasAges 18–75 - NCT05112237Recruiting
Study of children’s heart disease caused by MYBPC3 gene changes
This is an observational study that follows children under 18 with cardiomyopathy caused by certain MYBPC3 gene mutations. It aims to better understand how the disease changes over time, which may help future treatments be better targeted.
Dallas, TexasAges birth–18 years - NCT05489705Recruiting
Real-world registry for mavacamten and other obstructive HCM treatments
This study collects real-world information about people with obstructive hypertrophic cardiomyopathy (HCM) who are being treated with mavacamten or other standard medicines. It aims to understand patient characteristics, treatment choices over time, and long-term outcomes.
Dallas, TexasAges 18 years+ - NCT06128629RecruitingPhase 3
A study of NTLA-2001 for transthyretin amyloidosis with heart problems
This study tests a new treatment, NTLA-2001, for people with a type of heart disease called transthyretin amyloidosis with cardiomyopathy. It aims to see if the medicine can help improve heart function and quality of life.
Houston, TexasAges 18–90 - NCT07023614RecruitingPhase 2
Study of Ninerafaxstat for Non-Obstructive Hypertrophic Cardiomyopathy
This trial tests an investigational drug (ninerafaxstat) for people with a specific type of thickened heart muscle called non-obstructive hypertrophic cardiomyopathy. The goal is to see if the drug can improve symptoms and exercise ability.
Houston, TexasAges 18 years+ - NCT06679946Enrolling by invitationPhase 3
Study of Vutrisiran for heart condition from TTR amyloidosis
This study tests a drug called vutrisiran for people with a condition called transthyretin amyloidosis that affects the heart. It is for patients who have already been in certain earlier studies of patisiran or vutrisiran.
Dallas, TexasAges 18 years+ - NCT06461468Enrolling by invitation
AI study for hypertrophic cardiomyopathy using heart tests
This study uses artificial intelligence to analyze ECGs and echoes from people with hypertrophic cardiomyopathy (HCM) to improve how the disease is detected and managed. If you have HCM with a thickened heart wall and available heart tests, you may help train the AI.
Dallas, TexasAges 18 years+ - NCT05667493Enrolling by invitationPhase 3
Long-term safety follow-up for eplontersen in ATTR heart disease
This is a long-term study to check the safety of eplontersen over time in adults with transthyretin-mediated amyloid cardiomyopathy (ATTR-CM). It is mainly for people who already took the study medication before, or who joined an earlier related study and are doing well.
Houston, TexasAges 18 years+ - NCT06080074RecruitingPhase 2
Emergency heart-lung machine study for children with severe heart failure
This study tests a specific heart-lung machine called Cardiohelp to help children with severe heart failure. It looks at how well the machine works and whether a blood thinner (either heparin or bivalirudin) is safer and more effective.
Dallas, TexasAges birth–16 years - NCT07207811RecruitingPhase 3
Study of coramitug for heart failure from ATTR amyloidosis
This study tests an investigational medicine called coramitug in people with heart failure caused by ATTR amyloidosis, a condition where abnormal protein builds up in the heart. The goal is to see if it can slow or improve heart function.
Austin, TexasAges 18 years+ - NCT05511246RecruitingPhase 2
Alcohol injection for fast heart rhythm
This trial tests injecting ethanol (alcohol) into a vein near the heart to treat a dangerous fast heart rhythm called ventricular tachycardia. It may be an option for people who have an implanted defibrillator and have not found relief with other treatments.
Houston, TexasAges 18–85 - NCT05034432RecruitingPhase 4
Test treatment for dangerous heart rhythm episodes in LVAD patients
This trial studies a procedure to fix abnormal heart rhythms (ventricular tachycardia or ventricular fibrillation) in people who have an LVAD and a defibrillator (ICD) or an alternative device. It may help prevent future dangerous rhythm episodes after LVAD treatment.
Houston, TexasAges 18 years+ - NCT04504188Recruiting
Adjusting beta-blocker dose for women using a wearable defibrillator
This trial checks whether doctors can use a lower or adjusted dose of beta-blocker medicine in women who are wearing a wearable defibrillator (WCD). It aims to find an approach that’s safe and works while you’re using the device for about 3 months to protect your heart.
McKinney, TexasAges 18 years+ - NCT05489549Recruiting
Study of heart amyloid risk in people with TTR gene variants
This study looks at people who carry certain TTR gene variants, which can cause a specific type of heart amyloid buildup. It also includes people with symptoms, to understand how the condition develops and how it may be monitored.
Dallas, TexasAges 30–80 - NCT05650658Recruiting
Compare two heart pacing options in people with weak heart function
This trial compares two types of “left-side” heart pacing to see which one works better in people with weak heart pumping. It may help guide the best pacing choice for improving heart function and symptoms.
Arlington, TexasAges 18 years+
Cardiomyopathies trials by city in Texas
Where these studies are running in Texas
Institutions with a site for the recruiting cardiomyopathies studies listed above.
- Houston Methodist Hospital · 9 studies
- University of Texas Southwestern Medical Center · 8 studies
- Baylor College of Medicine · 4 studies
- Baylor Scott & White Research Institute · 3 studies
- Baylor Scott & White The Heart Hospital - Plano · 3 studies
- Clinical Trial Site · 2 studies
- Ascension Texas Cardiovascular
- Austin Heart
What taking part in a cardiomyopathies study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Cardiomyopathies trials in other states
Common questions
- Are there cardiomyopathies clinical trials in Texas?
- Yes. We're currently tracking 37 recruiting cardiomyopathies studies with a site in Texas, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a cardiomyopathies study in Texas?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Texas to take part?
- Not necessarily. These studies have a site in Texas, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a cardiomyopathies trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New cardiomyopathies studies open in Texas regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.